$-0.07 EPS Expected for Oasmia Pharmaceutical AB (OASM)

August 26, 2017 – By Dolores Ford

Analysts await Oasmia Pharmaceutical AB (STO:OASM) to report earnings on September, 1. After $-0.12 actual EPS reported by Oasmia Pharmaceutical AB for the previous quarter, Wall Street now forecasts -41.67 % EPS growth. The stock increased 1.06% or $0.03 on August 25, reaching $2.85. About 490,970 shares traded or 9.51% up from the average. Oasmia Pharmaceutical AB (STO:OASM) has declined 35.00% since August 26, 2016 and is downtrending. It has underperformed by 51.70% the S&P500.

Oasmia Pharmaceutical AB is a Sweden pharmaceutical firm engaged in the field of human and veterinary oncology. The company has market cap of $503.13 million. The Company’s activities are divided into two divisions: Human Health and Animal Health. It currently has negative earnings. The Human Health segment specializes in ovarian and breast cancer.

More notable recent Oasmia Pharmaceutical AB (STO:OASM) news were published by: Globenewswire.com which released: “Issuance of warrants in Oasmia Pharmaceutical AB (publ)” on June 21, 2017, also Globenewswire.com with their article: “Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue” published on June 19, 2017, Globenewswire.com published: “Oasmia Pharmaceutical to spin-off veterinary assets” on May 10, 2017. More interesting news about Oasmia Pharmaceutical AB (STO:OASM) were released by: Globenewswire.com and their article: “NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB” published on August 25, 2017 as well as Globenewswire.com‘s news article titled: “Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm …” with publication date: May 23, 2017.